Steward Partners Investment Advisory LLC Purchases 3,942 Shares of Royalty Pharma plc (NASDAQ:RPRX)

Steward Partners Investment Advisory LLC raised its position in shares of Royalty Pharma plc (NASDAQ:RPRX) by 806.1% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 4,431 shares of the biopharmaceutical company’s stock after purchasing an additional 3,942 shares during the period. Steward Partners Investment Advisory LLC’s holdings in Royalty Pharma were worth $113,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also bought and sold shares of the company. Brooklyn Investment Group raised its position in Royalty Pharma by 1,006.9% during the 4th quarter. Brooklyn Investment Group now owns 963 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 876 shares in the last quarter. Allworth Financial LP raised its position in shares of Royalty Pharma by 417.6% in the 4th quarter. Allworth Financial LP now owns 1,087 shares of the biopharmaceutical company’s stock worth $28,000 after acquiring an additional 877 shares in the last quarter. Riverview Trust Co raised its position in shares of Royalty Pharma by 3,953.3% in the 4th quarter. Riverview Trust Co now owns 1,216 shares of the biopharmaceutical company’s stock worth $31,000 after acquiring an additional 1,186 shares in the last quarter. Fifth Third Bancorp raised its position in shares of Royalty Pharma by 187.1% in the 4th quarter. Fifth Third Bancorp now owns 1,530 shares of the biopharmaceutical company’s stock worth $39,000 after acquiring an additional 997 shares in the last quarter. Finally, Blue Trust Inc. raised its position in shares of Royalty Pharma by 31.3% in the 4th quarter. Blue Trust Inc. now owns 1,579 shares of the biopharmaceutical company’s stock worth $45,000 after acquiring an additional 376 shares in the last quarter. 54.35% of the stock is owned by institutional investors.

Royalty Pharma Stock Up 0.3 %

Shares of RPRX stock opened at $32.77 on Monday. Royalty Pharma plc has a 1-year low of $24.05 and a 1-year high of $34.20. The stock’s fifty day moving average price is $31.58 and its 200 day moving average price is $28.56. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.44 and a quick ratio of 1.44. The company has a market cap of $18.89 billion, a price-to-earnings ratio of 22.60, a price-to-earnings-growth ratio of 2.31 and a beta of 0.47.

Royalty Pharma (NASDAQ:RPRX) last announced its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.15 earnings per share for the quarter, topping the consensus estimate of $0.99 by $0.16. Royalty Pharma had a return on equity of 24.40% and a net margin of 37.94%. On average, research analysts expect that Royalty Pharma plc will post 4.49 earnings per share for the current fiscal year.

Royalty Pharma Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, March 10th. Investors of record on Friday, February 21st were paid a dividend of $0.22 per share. This represents a $0.88 annualized dividend and a yield of 2.69%. This is an increase from Royalty Pharma’s previous quarterly dividend of $0.21. The ex-dividend date of this dividend was Friday, February 21st. Royalty Pharma’s payout ratio is 60.69%.

Analysts Set New Price Targets

Separately, TD Cowen raised Royalty Pharma to a “strong-buy” rating in a research report on Tuesday, December 24th. One investment analyst has rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Buy” and an average target price of $41.60.

Royalty Pharma Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.